ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.55
-0.76 (-5.31%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.31
Open14.21
Bid6.75 x 1300
Ask13.53 x 800
Day's Range13.51 - 14.51
52 Week Range13.29 - 25.82
Volume394,774
Avg. Volume375,463
Market Cap741.541M
Beta (3Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.30
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced favorable results from  the second part  of its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone in patients with stable symptoms of schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held in Hollywood, FL, December 9-13, 2018. Poster T184 entitled "Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia" is being presented today from 5:30 pm — 7:30 pm during Poster Session II. The poster presented data demonstrating that lumateperone, administered for up to one year, was generally well tolerated and exhibited statistically significant improvements from baseline on key safety measures of body weight, cardiometabolic and endocrine parameters, without motor side effects often associated with other antipsychotic medications.

  • GlobeNewswire6 days ago

    Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2019. “The FDA’s acceptance of our NDA submission for lumateperone for the treatment of schizophrenia represents an important milestone and brings us closer to offering a potential advance in the treatment of patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT

    Q3 2018 Intra-Cellular Therapies Inc Earnings Call

  • Simply Wall St.last month

    Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?

    If you own shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Associated Presslast month

    Intra-Cellular: 3Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 76 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2018. This portion of the study follows patients for up to 1-year of treatment with lumateperone after a switch from standard-of-care antipsychotic therapy.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast

    NEW YORK, Nov. 01, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease

    Intra-Cellular Therapies, Inc. (ITCI) today announced topline results from the Company’s Phase 1/2 clinical study evaluating ITI-214, its potent and selective phosphodiesterase 1 (PDE1) inhibitor, in patients with mild-to-moderate Parkinson’s disease (PD) maintained on stable (concomitant) PD medication (e.g., dopamine replacement therapies). The primary objective of this Phase 1/2, randomized, double-blind, placebo-controlled, multiple ascending dose cohort study was to evaluate the safety and tolerability of ITI-214 and to explore the potential for ITI-214 to treat both motor and non-motor symptoms associated with PD. Topline results demonstrate ITI-214 was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present top line results from the Company’s Phase 1/2 clinical study of ITI-214, its potent and selective phosphodiesterase 1 (PDE1) inhibitor, in patients with mild to moderate Parkinson’s disease (PD) being maintained on stable (concomitant) PD medication, at the 2018 American Neurological Association Annual Meeting being held in Atlanta, Georgia, October 21-24, 2018.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer

    NEW YORK, Oct. 16, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?

    Intra-Cellular Therapies has been struggling lately, but the selling pressure may be coming to an end soon.

  • Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock

    Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumateperone, a once-daily, oral investigational medicine with a novel mechanism of action for the treatment of schizophrenia.   The NDA submission is supported by data from 20 clinical trials and more than 1,900 subjects exposed to lumateperone. Lumateperone received Fast Track designation from the FDA in November 2017 for the treatment of schizophrenia.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company?
    Simply Wall St.3 months ago

    Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Intra-Cellular Therapies Inc (NASDAQ:ITCI), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger4 months ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ITCI earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Intra-Cellular Therapies Inc Earnings Call

  • Associated Press5 months ago

    Intra-Cellular: 2Q Earnings Snapshot

    The New York-based company said it had a loss of 68 cents per share. Intra-Cellular shares have risen 43 percent since the beginning of the year. The stock has increased 84 percent in the last 12 months. ...

  • ACCESSWIRE5 months ago

    Intra-Cellular Therapies, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern ...